This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thomson Reuters Life Sciences Cortellis Competitive Intelligence Reaches Content Milestones

PHILADELPHIA, July 24, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced a series of industry-first milestones in its Cortellis platform. Cortellis, the premier source of life sciences competitive intelligence information and analytics, has reached new content milestones with more than 50,000 investigational drugs, 400,000 bioactive compounds, and six million biologically active patents. In total, the solution contains over 15 million expert, human-curated reports featuring deal information, patents, literature and clinical trials data.

The Cortellis milestones are in addition to new data being integrated into the platform as a result of three recent acquisitions. These include Deloitte Recap, the leading biopharmaceutical provider of life science deals, acquisitions data and analytics; BioWorld and Medical Device Daily, premiere daily news sources in the biopharma and medical device industries; and Timely Data Resources, the esteemed provider of epidemiology information for biopharmaceutical companies, device manufacturers, universities and research institutions. This collective content confirms Cortellis as the industry leading solution for drug discovery, development and commercialization.

"Given the overwhelming amount of public data available, life science professionals need a way to access accurate and relevant information and analytics to support strategic decisions throughout the drug development process," said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. "Their need underscores the reasoning behind our editorial process and unique Cortellis technology: make the best content findable and actionable for our pharmaceutical customers. Our recent milestones in content breadth, as well as our recent acquisitions, add to the decision-making power we give these professionals."

Thomson Reuters employs a rigorous review process for each investigational drug featured in Cortellis. The editorial team combs through two-to-three year's worth of information, compiling a unique profile that includes basic drug information as well as recent news articles, publications, events, and more. Users benefit from an all-in-one-place summary of the compound, without having to spend days researching and parsing information on their own.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,164.61 +190.30 1.12%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.4230 +17.1970 0.38%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs